LEEVOXY-250 Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
LEEVOXY-250
Levofloxacin 250mg
LEEVOXY-250 is a broad-spectrum bactericidal antimicrobial agent exhibiting enhanced pharmacokinetic tissue penetration against susceptible gram-positive and gram-negative pathogens.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
Inhibits bacterial DNA gyrase (type II topoisomerase) and topoisomerase IV enzymes required for bacterial DNA replication, transcription, and repair.
Adult: One dose once or twice daily depending on infectious severity. Complete full course to prevent antimicrobial resistance.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store below 25°C in a dry place. Protect from moisture and direct sunlight.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
LEEVOXY-250 features Levofloxacin 250mg prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 2 verified reviews
High therapeutic compliance and optimal bio-absorption
Prescribed LEEVOXY-250 extensively in our OPD practice. Excellent bioavailability, quick absorption, and well-tolerated across diverse patient demographics. The quality of active pharmaceutical ingredients (API) is visibly superior compared to market alternatives.
Reliable distribution partner with certified DCGI standards
Stocking LEEVOXY-250 has been very profitable and smooth for our distribution agency. Doctors trust the brand, billing is prompt, and goods arrive in reinforced thermocol carton packing with zero transit breakage. A genuine 5-star pharmaceutical product.
Questions Regarding LEEVOXY-250
What is the therapeutic indication and composition of LEEVOXY-250?
LEEVOXY-250 contains Levofloxacin 250mg indicated for Lower Respiratory Tract Infections as formulated by Sygnus Biotech.
What packaging presentations are available for LEEVOXY-250?
LEEVOXY-250 is supplied in tamper-evident 10 x 10 Alu-Alu / Blister Pack, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for LEEVOXY-250?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for LEEVOXY-250 along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
LEEVOXY-250 is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.
Related Formulations in Tablet
View all Tablet →
DAIBET-G2 V
Glimepiride 2mg + Metformin Hydrochloride 500mg + Voglibose 0.2mg Bilayered
SBTEL-M 25
Telmisartan 40mg + Metoprolol Succinate 23.75mg + Metoprolol Tartrate 25mg